naag peptidase NAAG peptidase inhibition enhances long-term (24 h delay) memory - Folh1 ZJ43 is a potent NAAG peptidase inhibitor Understanding NAAG Peptidase: Function, Inhibition, and Therapeutic Potential

Pluvicto NAAG peptidase, also known as glutamate carboxypeptidase II (GCPII), is an enzyme that plays a significant role in the central nervous systemNaag Peptidase and Neuronal Function - Joseph Neale. Its primary function involves the breakdown of N-acetyl-L-aspartyl-L-glutamate (NAAG), a neuropeptide, into N-acetylaspartate (NAA) and glutamate. This enzymatic activity is crucial for regulating the levels of these signaling molecules in the brain, influencing neurotransmission and neuronal functionGlutamate carboxypeptidase II.

The Role of NAAG and NAAG Peptidase in the Nervous System

NAAG itself is recognized as the most abundant dipeptide in the mammalian brain. It acts as a neuromodulator and is particularly important in glutamatergic synapses.NAAG peptidase inhibitors: Broad efficacy in... | Posters NAAG has been shown to activate group II metabotropic glutamate receptors, specifically mGluR3, and can influence the release of substances like glutamate. Research indicates that NAAG decreases the release of glutamate by activating presynaptic group II mGlu receptors and stimulates the release of trophic factors from glia.

The enzyme NAAG peptidase is essential for controlling the concentration of NAAGNAAG peptidase inhibitors and deletion of .... GCPII is a class II membrane glycoprotein that catalyzes the hydrolysis of NAAG to glutamate and N-acetylaspartate (NAA). This inactivation process by glutamate carboxypeptidases II (GCPII), and potentially GCPIII, ensures that NAAG levels are maintained within a physiological range. Without adequate peptidase activity, NAAG could accumulate, leading to dysregulation of neurotransmitter systems.

Therapeutic Implications of NAAG Peptidase Inhibition

Modulation of NAAG peptidase activity through inhibitors has emerged as a promising therapeutic strategy for a variety of neurological and psychiatric conditions. NAAG peptidase inhibition holds potential for neuroprotection by simultaneously increasing NAAG levels and decreasing excess glutamate release.NAAG peptidase inhibitors block cognitive deficit induced ...

Studies have explored the effects of NAAG peptidase inhibitors in various contexts:

* Cognitive Function: NAAG peptidase inhibition improves cognition, as demonstrated in tests like novel object recognition. This suggests its potential in treating cognitive deficits associated with certain neurological disorders. For example, NAAG peptidase inhibition enhances long-term (24 h delay) memory.

* Pain Management: Research indicates that NAAG peptidase inhibition can attenuate pain responses. For instance, it has been shown to reduce allodynia following inflammatory insults.

* Neuroprotection: NAAG peptidase inhibitor ZJ-43 has been identified as a potential strategy to reduce neuronal and astrocyte damage associated with conditions like stroke or traumatic brain injury.作者：T Yamada·2012·被引用次数：44—These data demonstrate a behavioral and neurochemical role forNAAGin the PAG and RVM in regulating the spinal motor response to inflammation and thatNAAG... Fluid percussion brain injury studies in rats have shown that a NAAG peptidase inhibitor increases levels of NAAG and reduces extracellular glutamate, aspartate, and GABA levels in the dorsal hippocampus.

* Psychiatric Disorders: The impact of NAAG peptidase inhibition on behaviors induced by substances like PCP has been investigated. While NAAG peptidase inhibition will reduce some of the PCP-induced behaviors, it may not affect all of them, indicating a complex role in the underlying neurochemistry.

Key Inhibitors and Their Mechanisms

Several compounds have been developed as NAAG peptidase inhibitors.ZJ43 is a potent NAAG peptidase inhibitor, with an IC50 of 2.4 nM and a Ki of 0.8 nM. ZJ43 sufficiently activates group II mGluR and reduces some of the ... ZJ43 is a potent NAAG peptidase inhibitor, with reported IC50 and Ki values in the nanomolar rangeNAAG peptidase inhibitor increases levels of .... ZJ 43 is a potent inhibitor of glutamate carboxypeptidase II and III (GCP II and III/NAAG peptidase/NAALADase). These inhibitors work by binding to the enzyme's active site, preventing it from breaking down NAAGAntinociceptive effects of N-acetylaspartylglutamate (NAAG .... Another notable inhibitor is 2-(phosphonomethyl) pentanedioic acid (2-PMPA), which acts as a competitive NAAG peptidase inhibitor.NAAGconsists of N-acetylaspartic acid (NAA) and glutamic acid coupled via a peptide bond. N-Acetylaspartylglutamic acid ...

The mechanism by which these inhibitors exert their effects often involves their interaction with metabotropic glutamate receptors.Parallel Metabolomics and Lipidomics of a PSMA/GCPII ... As mentioned, NAAG activates group II metabotropic glutamate receptors (mGluR), with a preference for mGluR3NAAG peptidase inhibitor increases levels of .... NAAG peptidase inhibitors act via mGluR3, leading to downstream effects on neurotransmission.

NAAG Peptidase in Disease and Beyond

Beyond its role in normal brain function, NAAG peptidase and its inhibitors are being investigated for their involvement in various disease states, including cancer. Some studies have reported the roles of NAAG in cancer, touching upon its involvement in energy storage and metabolic cycling作者：KJ Janczura·2013·被引用次数：34—The objective of this study was to test the hypothesis thatNAAG peptidase inhibition enhances long-term (24 h delay) memoryof C57BL mice..

Furthermore, research has identified NAAG-like immunoreactivity in neurons and presumptive synaptic endings, highlighting its widespread presence and functional significance. The metabolism of NAAG has also been a target of investigation, with extrinsic NAAG-like substances sometimes inhibiting NAAG peptidase by competing with NAAG for the enzyme's active site.

The ongoing research into NAAG peptidase and its inhibition continues to shed light on its fundamental biological processes and its potential to serve as a novel therapeutic approach for a range of debilitating conditionsParallel Metabolomics and Lipidomics of a PSMA/GCPII .... The development of specific NAAG peptidase inhibitors like ZJ 43 offers exciting avenues for future clinical applications.